Research ArticleOriginal Article

CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells

Rosaria A. Fontanella, Silvia Sideri, Chiara Di Stefano, Angiolina Catizone, Silvia Di Agostino, Daniela F. Angelini, Gisella Guerrera, Luca Battistini, Giulia Battafarano, Andrea Del Fattore, Antonio Francesco Campese, Fabrizio Padula, Paola De Cesaris, Antonio Filippini and Anna Riccioli
Cancer Biology & Medicine August 2021, 18 (3) 788-807; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0495

References

  1. 1.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.
    Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7–34.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Macedo F,
    3. Ladeira K,
    4. Pinho F,
    5. Saraiva N,
    6. Bonito N,
    7. Pinto L, et al.
    Bone metastases: an overview. Oncol Rev. 2017; 11: 321.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Di Stefano C,
    3. Grazioli P,
    4. Fontanella RA,
    5. De Cesaris P,
    6. D’Amore A,
    7. Regno M, et al.
    Stem-like and highly invasive prostate cancer cells expressing CD44v8-10 marker originate from CD44-negative cells. Oncotarget. 2018; 9: 30905–18.
    OpenUrl
  4. 4.↵
    2. Li H,
    3. Chen X,
    4. Calhoun-Davis T,
    5. Claypool K,
    6. Tang DG.
    PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res. 2008; 68: 1820–5.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Underhill C.
    CD44: the hyaluronan receptor. J Cell Sci. 1992; 103(Pt 2): 293–8.
    OpenUrlFREE Full Text
  6. 6.↵
    2. Matsumura Y,
    3. Tarin D.
    Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet. 1992; 340: 1053–8.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Ni J,
    3. Cozzi PJ,
    4. Hao JL,
    5. Beretov J,
    6. Chang L,
    7. Duan W, et al.
    CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate. 2014; 74: 602–17.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Hu J,
    3. Li G,
    4. Zhang P,
    5. Zhuang X,
    6. Hu G.
    A cd44v(+) subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity. Cell Death Dis. 2017; 8: e2679.
  9. 9.↵
    2. Yae T,
    3. Tsuchihashi K,
    4. Ishimoto T,
    5. Motohara T,
    6. Yoshikawa M,
    7. Yoshida GJ, et al.
    Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 2012; 3: 883.
    OpenUrlCrossRefPubMed
  10. 10.↵
    2. Zhang H,
    3. Brown RL,
    4. Wei Y,
    5. Zhao P,
    6. Liu S,
    7. Liu X, et al.
    CD44 splice isoform switching determines breast cancer stem cell state. Genes Dev. 2019; 33: 166–79.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Zhao P,
    3. Xu Y,
    4. Wei Y,
    5. Qiu Q,
    6. Chew TL,
    7. Kang Y, et al.
    The CD44s splice isoform is a central mediator for invadopodia activity. J Cell Sci. 2016; 129: 1355–65.
    OpenUrlAbstract/FREE Full Text
  12. 12.
    2. Reinke LM,
    3. Xu Y,
    4. Cheng C.
    Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition. J Biol Chem. 2012; 287: 36435–42.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Brown RL,
    3. Reinke LM,
    4. Damerow MS,
    5. Perez D,
    6. Chodosh LA,
    7. Yang J, et al.
    CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011; 121: 1064–74.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. Morel AP,
    3. Lievre M,
    4. Thomas C,
    5. Hinkal G,
    6. Ansieau S,
    7. Puisieux A.
    Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008; 3: e2888.
  15. 15.↵
    2. Mani SA,
    3. Guo W,
    4. Liao MJ,
    5. Eaton EN,
    6. Ayyanan A,
    7. Zhou AY, et al.
    The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133: 704–15.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    2. Jadaan DY,
    3. Jadaan MM,
    4. McCabe JP.
    Cellular plasticity in prostate cancer bone metastasis. Prostate Cancer. 2015; 2015: 651580.
    OpenUrlPubMed
  17. 17.↵
    2. Liao TT,
    3. Yang MH.
    Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness. Mol Oncol. 2017; 11: 792–804.
    OpenUrl
  18. 18.↵
    2. Koeneman KS,
    3. Yeung F,
    4. Chung LW.
    Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate. 1999; 39: 246–61.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    2. Coleman RE.
    Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27: 165–76.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    2. Mundy GR.
    Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584–93.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Rossi M,
    3. Battafarano G,
    4. D’Agostini M,
    5. Del Fattore A.
    The role of extracellular vesicles in bone metastasis. Int J Mol Sci. 2018; 19: 1136.
    OpenUrl
  22. 22.↵
    2. Ara T,
    3. Declerck YA.
    Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer. 2010; 46: 1223–31.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    2. Tsukamoto H,
    3. Fujieda K,
    4. Senju S,
    5. Ikeda T,
    6. Oshiumi H,
    7. Nishimura Y.
    Immune-suppressive effects of interleukin-6 on t-cell-mediated anti-tumor immunity. Cancer Sci. 2018; 109: 523–30.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Orian-Rousseau V.
    CD44, a therapeutic target for metastasising tumors. Eur J Cancer. 2010; 46: 1271–7.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    2. Tanabe KK,
    3. Ellis LM,
    4. Saya H.
    Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet. 1993; 341: 725–6.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    2. Gunthert U,
    3. Hofmann M,
    4. Rudy W,
    5. Reber S,
    6. Zoller M,
    7. Haussmann I, et al.
    A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991; 65: 13–24.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    2. Bourguignon LY,
    3. Wong G,
    4. Earle C,
    5. Chen L.
    Hyaluronan-CD44v3 interaction with Oct4-Sox2-nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2012; 287: 32800–24.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    2. Lau WM,
    3. Teng E,
    4. Chong HS,
    5. Lopez KA,
    6. Tay AY,
    7. Salto-Tellez M, et al.
    CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 2014; 74: 2630–41.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    2. Kato T,
    3. Mizutani K,
    4. Kawakami K,
    5. Fujita Y,
    6. Ehara H,
    7. Ito M.
    CD44v8-10 mRNA contained in serum exosomes as a diagnostic marker for docetaxel resistance in prostate cancer patients. Heliyon. 2020; 6: e04138.
  30. 30.↵
    2. Yu S,
    3. Cai X,
    4. Wu C,
    5. Wu L,
    6. Wang Y,
    7. Liu Y, et al.
    Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression. Oncotarget. 2015; 6: 2951–65.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Schmitt M,
    3. Metzger M,
    4. Gradl D,
    5. Davidson G,
    6. Orian-Rousseau V.
    CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ. 2015; 22: 677–89.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Chan SW,
    3. Lim CJ,
    4. Guo K,
    5. Ng CP,
    6. Lee I,
    7. Hunziker W, et al.
    A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res. 2008; 68: 2592–8.
    OpenUrlAbstract/FREE Full Text
  33. 33.
    2. Deel MD,
    3. Li JJ,
    4. Crose LE,
    5. Linardic CM.
    A review: molecular aberrations within hippo signaling in bone and soft-tissue sarcomas. Front Oncol. 2015; 5: 190.
    OpenUrlCrossRef
  34. 34.
    2. Panciera T,
    3. Citron A,
    4. Di Biagio D,
    5. Battilana G,
    6. Gandin A,
    7. Giulitti S, et al.
    Reprogramming normal cells into tumour precursors requires ecm stiffness and oncogene-mediated changes of cell mechanical properties. Nat Mater. 2020; 19: 797–806.
    OpenUrl
  35. 35.↵
    2. Zanconato F,
    3. Battilana G,
    4. Cordenonsi M,
    5. Piccolo S.
    YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol. 2016; 29: 26–33.
    OpenUrlCrossRef
  36. 36.↵
    2. Moroishi T,
    3. Hansen CG,
    4. Guan KL.
    The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015; 15: 73–9.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Zeng Y,
    3. Wodzenski D,
    4. Gao D,
    5. Shiraishi T,
    6. Terada N,
    7. Li Y, et al.
    Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res. 2013; 73: 4123–33.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Warzecha CC,
    3. Jiang P,
    4. Amirikian K,
    5. Dittmar KA,
    6. Lu H,
    7. Shen S, et al.
    An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J. 2010; 29: 3286–300.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    2. Oshima RG,
    3. Baribault H,
    4. Caulin C.
    Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev. 1996; 15: 445–71.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    2. Kumar B,
    3. Koul S,
    4. Khandrika L,
    5. Meacham RB,
    6. Koul HK.
    Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008; 68: 1777–85.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell. 2015; 163: 1011–25.
    OpenUrlCrossRefPubMed
  42. 42.↵
    2. Tang Z,
    3. Kang B,
    4. Li C,
    5. Chen T,
    6. Zhang Z.
    GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47: W556–60.
    OpenUrlCrossRefPubMed
  43. 43.↵
    2. Bonnomet A,
    3. Syne L,
    4. Brysse A,
    5. Feyereisen E,
    6. Thompson EW,
    7. Noel A, et al.
    A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. 2012; 31: 3741–53.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    2. Akech J,
    3. Wixted JJ,
    4. Bedard K,
    5. van der Deen M,
    6. Hussain S,
    7. Guise TA, et al.
    Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 2010; 29: 811–21.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    2. Dougall WC.
    Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012; 18: 326–35.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    2. Kovacs B,
    3. Vajda E,
    4. Nagy EE.
    Regulatory effects and interactions of the Wnt and OPG-RANKL-RANK signaling at the bone-cartilage interface in osteoarthritis. Int J Mol Sci. 2019; 20: 4653.
    OpenUrl
  47. 47.↵
    2. Hall CL,
    3. Bafico A,
    4. Dai J,
    5. Aaronson SA,
    6. Keller ET.
    Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005; 65: 7554–60.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    2. Azzolin L,
    3. Zanconato F,
    4. Bresolin S,
    5. Forcato M,
    6. Basso G,
    7. Bicciato S, et al.
    Role of TAZ as mediator of Wnt signaling. Cell. 2012; 151: 1443–56.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    2. Udagawa N,
    3. Takahashi N,
    4. Katagiri T,
    5. Tamura T,
    6. Wada S,
    7. Findlay DM, et al.
    Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med. 1995; 182: 1461–8.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    2. Butte MJ,
    3. Keir ME,
    4. Phamduy TB,
    5. Sharpe AH,
    6. Freeman GJ.
    Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27: 111–22.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    2. Shen MM,
    3. Abate-Shen C.
    Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24: 1967–2000.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    2. Bae KM,
    3. Parker NN,
    4. Dai Y,
    5. Vieweg J,
    6. Siemann DW.
    E-cadherin plasticity in prostate cancer stem cell invasion. Am J Cancer Res. 2011; 1: 71–84.
    OpenUrlPubMedWeb of Science
  53. 53.↵
    2. Fontana F,
    3. Raimondi M,
    4. Marzagalli M,
    5. Sommariva M,
    6. Limonta P,
    7. Gagliano N.
    Epithelial-to-mesenchymal transition markers and CD44 isoforms are differently expressed in 2D and 3D cell cultures of prostate cancer cells. Cells. 2019; 8: 143.
    OpenUrl
  54. 54.↵
    2. Yilmaz M,
    3. Christofori G.
    Mechanisms of motility in metastasizing cells. Mol Cancer Res. 2010; 8: 629–42.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    2. Gagliano N,
    3. Sforza C,
    4. Sommariva M,
    5. Menon A,
    6. Conte V,
    7. Sartori P, et al.
    3D-spheroids: what can they tell us about pancreatic ductal adenocarcinoma cell phenotype? Exp Cell Res. 2017; 357: 299–309.
    OpenUrl
  56. 56.↵
    2. Pastushenko I,
    3. Brisebarre A,
    4. Sifrim A,
    5. Fioramonti M,
    6. Revenco T,
    7. Boumahdi S, et al.
    Identification of the tumour transition states occurring during EMT. Nature. 2018; 556: 463–8.
    OpenUrlCrossRefPubMed
  57. 57.↵
    2. Gao Y,
    3. Bado I,
    4. Wang H,
    5. Zhang W,
    6. Rosen JM,
    7. Zhang XH.
    Metastasis organotropism: redefining the congenial soil. Dev Cell. 2019; 49: 375–91.
    OpenUrl
  58. 58.↵
    2. Khandrika L,
    3. Kumar B,
    4. Koul S,
    5. Maroni P,
    6. Koul HK.
    Oxidative stress in prostate cancer. Cancer Lett. 2009; 282: 125–36.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    2. Juan-Rivera MC,
    3. Martinez-Ferrer M.
    Integrin inhibitors in prostate cancer. Cancers (Basel). 2018; 10: 44.
    OpenUrl
  60. 60.↵
    2. Lee YC,
    3. Jin JK,
    4. Cheng CJ,
    5. Huang CF,
    6. Song JH,
    7. Huang M, et al.
    Targeting constitutively activated beta1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013; 11: 405–17.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    2. Katagiri YU,
    3. Sleeman J,
    4. Fujii H,
    5. Herrlich P,
    6. Hotta H,
    7. Tanaka K, et al.
    CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res. 1999; 59: 219–26.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    2. Collins AT,
    3. Habib FK,
    4. Maitland NJ,
    5. Neal DE.
    Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci. 2001; 114: 3865–72.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    2. Hiraga T,
    3. Ito S,
    4. Nakamura H.
    Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013; 73: 4112–22.
    OpenUrlAbstract/FREE Full Text
  64. 64.↵
    2. Hiraga T,
    3. Nakamura H.
    Comparable roles of CD44v8-10 and CD44s in the development of bone metastases in a mouse model. Oncol Lett. 2016; 12: 2962–9.
    OpenUrl
  65. 65.↵
    2. Chua CW,
    3. Chiu YT,
    4. Yuen HF,
    5. Chan KW,
    6. Man K,
    7. Wang X, et al.
    Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res. 2009; 15: 4322–35.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    2. Gupta A,
    3. Cao W,
    4. Chellaiah MA.
    Integrin alphavbeta3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-kappaB ligand signaling axis. Mol Cancer. 2012; 11: 66.
    OpenUrlCrossRefPubMed
  67. 67.↵
    2. Senbanjo LT,
    3. AlJohani H,
    4. AlQranei M,
    5. Majumdar S,
    6. Ma T,
    7. Chellaiah MA.
    Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cells. Cancer Drug Resist. 2020; 3: 586–602.
    OpenUrl
  68. 68.↵
    2. Senbanjo LT,
    3. AlJohani H,
    4. Majumdar S,
    5. Chellaiah MA.
    Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells. Cell Commun Signal. 2019; 17: 80.
    OpenUrl
  69. 69.↵
    2. Ouhtit A,
    3. Rizeq B,
    4. Saleh HA,
    5. Rahman MM,
    6. Zayed H.
    Novel CD44-downstream signaling pathways mediating breast tumor invasion. Int J Biol Sci. 2018; 14: 1782–90.
    OpenUrl
  70. 70.↵
    2. Gori F,
    3. Superti-Furga A,
    4. Baron R.
    Bone formation and the Wnt signaling pathway. N Engl J Med. 2016; 375: 1902–3.
    OpenUrl
  71. 71.↵
    2. Xiong J,
    3. Almeida M,
    4. O’Brien CA.
    The YAP/TAZ transcriptional co-activators have opposing effects at different stages of osteoblast differentiation. Bone. 2018; 112: 1–9.
    OpenUrlCrossRef
  72. 72.↵
    2. Byun MR,
    3. Hwang JH,
    4. Kim AR,
    5. Kim KM,
    6. Hwang ES,
    7. Yaffe MB, et al.
    Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation. Cell Death Differ. 2014; 21: 854–63.
    OpenUrlCrossRefPubMed
  73. 73.↵
    2. Liao J,
    3. Liu PP,
    4. Hou G,
    5. Shao J,
    6. Yang J,
    7. Liu K, et al.
    Regulation of stem-like cancer cells by glutamine through beta-catenin pathway mediated by redox signaling. Mol Cancer. 2017; 16: 51.
    OpenUrl
  74. 74.↵
    2. Knerr K,
    3. Ackermann K,
    4. Neidhart T,
    5. Pyerin W.
    Bone metastasis: osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. Int J Cancer. 2004; 111: 152–9.
    OpenUrlCrossRefPubMedWeb of Science
  75. 75.↵
    2. Axmann R,
    3. Bohm C,
    4. Kronke G,
    5. Zwerina J,
    6. Smolen J,
    7. Schett G.
    Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum. 2009; 60: 2747–56.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    2. Tsukamoto H,
    3. Fujieda K,
    4. Miyashita A,
    5. Fukushima S,
    6. Ikeda T,
    7. Kubo Y, et al.
    Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018; 78: 5011–22.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords